P28-11 The therapeutic efficacy of osimertinib in non-small cell lung cancer with malignant pleural effusion

Hiroaki Nagamine,Kenji Sawa,Hiroyasu Kaneda,Koichi Ogawa,Kenji Nakahama,Yoshiya Matsumoto,Yoko Tani,Shigeki Mitsuoka,Tatsuo Kimura,Tomoya Kawaguchi

ANNALS OF ONCOLOGY（2022）

引用 0|浏览1

暂无评分

摘要

Osimertinib is one of the standard first-line therapies for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, little is known about the clinical efficacy of osimertinib in NSCLC patients with malignant pleural effusion (MPE). Here, we evaluated the efficacy of osimertinib on these patients in the first line setting.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要